Long Term Outcomes and Safety Profile of Sirolimus in Post Liver Transplant Children.
No Thumbnail Available
All Authors
Fernandes Lucas, S.
Warner, S.
North-Lewis, P.
Mtegha, MP.
Jayaprakash, K.
Karthikeyan, P.
Rajwal, S.
LTHT Author
Warner, Suzan
North-Lewis, Penny
Mtegha, Marumbo
Jayaprakash, Kavitha
Karthikeyan, Palaniswamy
Rajwal, Sanjay
North-Lewis, Penny
Mtegha, Marumbo
Jayaprakash, Kavitha
Karthikeyan, Palaniswamy
Rajwal, Sanjay
LTHT Department
Leeds Children's Hospital
Children's Services
Medicines Management & Pharmacy Services
Clinical Pharmacy
Children's Liver Unit
Children's Services
Medicines Management & Pharmacy Services
Clinical Pharmacy
Children's Liver Unit
Non Medic
Pharmacist
Publication Date
2025
Item Type
Journal Article
Language
Subject
Subject Headings
Abstract
BACKGROUND: Tacrolimus is the maintenance immunosuppression of choice in pediatric liver transplant (LT) recipients. However, in selective cases, sirolimus is used as an alternative immunosuppressive treatment. We aimed to review a single centre's experience of using sirolimus as an alternative to tacrolimus in pediatric LT recipients.
METHODS: Single centre retrospective study of pediatric LT recipients who were started on sirolimus as an alternative immunosuppressant to tacrolimus. Children (< 16 years) who were started on sirolimus between May 2000 and May 2024 were included in the study.
RESULTS: A total of 19 children were started on sirolimus following LT and followed up for a median of 4 years (range 0.4-12.8). Post-transplant lymphoproliferative disorder (PTLD) was the most common reason for tacrolimus discontinuation and conversion to sirolimus (n = 14), followed by tacrolimus-related adverse effects (n = 4) and disease recurrence (n = 1). There were no cases of PTLD recurrence or biopsy-confirmed rejection whilst on sirolimus. Proteinuria and hyperlipidaemia were the most common sirolimus side effects observed. Eighteen children remain on sirolimus to date, and none required discontinuation from side effects. In those with PTLD, 4 episodes of rejection occurred between the period of tacrolimus discontinuation and starting sirolimus (median immunosuppression-free time of 5 months), with one child requiring regrafting due to chronic rejection.
CONCLUSION: The experience from our centre demonstrates sirolimus to be a safe and effective alternative to tacrolimus in a selected population of pediatric LT recipients. Further research with a larger sample size is required to confirm these findings and evaluate the long-term safety of sirolimus in this population.
Journal
Pediatric Transplantation